Download A role for orexin in central vestibular motor control and the

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
A role for orexin in central vestibular motor control
Jun ZHANG1, Bin LI1, Lei YU, Ye-Cheng HE, Hong-Zhao LI, Jing-Ning ZHU*, and Jian-Jun
WANG*
Department of Biological Science and Technology and State Key Laboratory of Pharmaceutical
Biotechnology, School of Life Sciences, Mailbox 426, Nanjing University, 22 Hankou Road,
Nanjing 210093, China
1
Co-first authors; * Corresponding authors
E-mail: [email protected]; [email protected]
The last decade has witnessed significant advances in our understanding of the physiological
roles of orexin (also known as hypocretin), a novel neuropeptide first identified in 1998. As a
neurotransmitter system originating uniquely from the lateral hypothalamus/perifornical area but
projecting extensively to almost the whole brain, the central orexinergic system has been
implicated in many basic nonsomatic functions, including the sleep/wake states, feeding, and
reward processes. However, whether the central orexinergic system has a role in somatic motor
control remains enigmatic. Intriguingly, orexin deficiency in humans, dogs, and rodents results in
cataplexy, a motor deficit characterized by sudden loss of muscle tone, highlighting the possibility
of a modulatory role for orexin in motor control. But, since cataplexy is closely related to
narcolepsy and often triggered by strong emotions, whether the effect of orexin on motor system is
secondary to its actions on the neural circuits controlling sleep or emotions is not clear. In the
present study, to reveal the exact relationship between the central orexinergic system and motor
control, the effects of orexin on the lateral vestibular nucleus (LVN), which holds a key position in
control of muscle tone and posture and receives orexinergic innervation, and the underlying
mechanisms were investigated at molecular, cellular, and behavioral levels. First, RT-PCR and
immunofluorescence results both showed that orexin 1 (OX1) and orexin 2 (OX2) receptors are
presented in the LVN in rats. Using brain slice preparations and whole-cell patch clamp recordings,
a dose-dependent inward current elicited by orexin-A were observed in giant LVN neurons
(diameter > 35 μm, Deiters’ neurons). The orexin-A-elicited inward currents on the LVN neurons
were not only partly blocked by selective OX1 receptor antagonist SB334867 but also mimicked
by selective OX2 receptor agonist [Ala11, D-Leu15]-orexin-B, indicating that the orexin-A-induced
excitation is mediated by both OX1 and OX2 receptors. Moreover, tetrodotoxin did not block the
excitations evoked by orexin-A, suggesting the actions of the peptide on LVN neurons are
postsynaptic. Coupled with the inward current, a slight decrease of membrane conductance of the
neurons elicited by orexin-A was observed and also was not blocked by tetrodotoxin, suggesting
that orexin-A causes a closure of ion channels on the postsynaptic membrane. The I-V curves
before and after application of orexin-A on LVN neurons showed that more than one ionic basis is
involved in the orexin-A-induced excitation. KB-R7943/SN-6 and Ba2+/tertiapin-Q, blockers for
Na+-Ca2+ exchangers and inward rectifier K+ channels respectively, together totally blocked the
orexin-A-elicited inward current. These results demonstrated that orexin-A excites the LVN
neurons via both activation of Na+-Ca2+ exchangers and closure of inward rectifier K+ channels.
1
Furthermore, current-clamp recordings revealed that orexin-A directly depolarized LVN neurons
and enhanced their sensitivities, and in vivo electrophysiological recordings also revealed that
microinjection of orexin-A into LVN excited adjacent LVN neurons. Moreover, unilateral
microinjection of orexin-A into the LVN caused animals not only head tilt but also rotating and
rolling movement, while bilateral microinjection of orexin-A significantly shortened the duration
of passage through the horizontal balance beam and the time spent for an upward 180º turn on an
inclined board, indicating a promotion of motor balance and negative geotaxis. Interestingly,
effects of endogenous orexin are critical when an animal is facing a major motor challenge as
opposed to during rest and general movements, as bilateral microinjection of SB334867 into LVN
impaired motor performance in inclined (40°) balance beam and rota-rod tests rather than in
horizontal balance beam and negative geotaxis tests. More interestingly, the decrement of motor
performance in accelerating rota-rod tests increased with the increase of the acceleration,
suggesting that the stronger the motor challenge faced by animals, the greater the degree of
involvement of the central orexinergic system in motor control. Therefore, the modulation of the
central orexinergic system on motor control may be not readily noticeable when internal and
external environments are relatively stable, as during rest or routine movements. During a
significant behavioral challenge, the increased excitatory drive and sensitivity due to the release of
orexin may be essential for ensuring prompt and appropriate magnitude motor responses, and
orexin deficiency results in cataplexy. In addition, bilateral microinjection of SB334867 into LVN
also did not affect both spontaneous locomotor and exploratory activity in an open-field. All these
results reveal that the central orexinergic system is directly and actively involved in
vestibular-related motor control. Therefore, orexin participates not only in sleep and emotion
(nonsomatic) but also in motor (somatic) regulation. Through parallel modulation of both somatic
and nonsomatic activities, the central orexinergic system may help to orchestrate an integrated and
coordinated somatic-nonsomatic response that leads to the appropriate behavioral response to
changes in the internal and external environment. Obviously, an intact behavior comprises both
somatic and nonsomatic components and needs a somatic-nonsomatic integration involving
various brain regions and discrete neuronal pathways. Here we speculate that the central
orexinergic system is an important component of the neural substrates responsible for
somatic-nonsomatic integration. We further suggest that narcolepsy-cataplexy caused by orexin
deficiency is a simultaneous somatic and nonsomatic dysfunction in which somatic (motor)
activities and some nonsomatic (sleep and emotional) responses are not correctly integrated and
coordinated. (Supported by grants 30670671, 30700201, 31070959, 31071021 and NSFC/RGC
Joint Research Scheme 30931160433 from the National Natural Science Foundation of China;
RFDP grant 20070284057 from the State Educational Ministry of China; grant BK2006713 from
the Natural Science Foundation of Jiangsu Province, China; grant 20100471305 from China
Postdoctoral Science Foundation; grant 0902067C from the Jiangsu Planned Projects for
Postdoctoral Research Funds; and grant CX09B_008Z from the Jiangsu Planned Projects for
Postgraduate Research and Innovation)
Keywords: Orexin; Central orexinergic system; Lateral vestibular nucleus; Motor control;
Cataplexy
2